RuiJian Medicine, a company focused on general cell therapy platforms, has secured 210 million RMB in its C1 funding round. The investment was co-led by Photosynthesis Ventures and Xingze Capital. These funds will be allocated to advancing the company's clinical pipeline, upgrading its AI-driven chemical induction platform, expanding production capabilities, and supporting global clinical development and international commercial collaborations. AI
IMPACT This funding will accelerate the development of AI in cell therapy, potentially leading to faster drug discovery and personalized treatments.
RANK_REASON Significant funding round for an AI-enabled biotech company. [lever_c_demoted from significant: ic=1 ai=0.7]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →